Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia

Abstract

Background-Hypercholesterolemia enhances platelet aggregability. Statins have beneficial effects on cardiovascular events. The purpose of this study is to investigate whether statins inhibit platelet aggregation and, if so, the mechanisms. Methods and Results-Twelve patients with hypercholesterolemia were prospectively randomized in a crossover design to receive either fluvastatin (20 mg/d) or colestimide (3000 mg/d) for 12 weeks. The subjects were switched to the opposite arm for additional 12 weeks. Before and after first and second treatments, experiments were performed. Eleven age-matched volunteers with normal lipid profiles served as controls. ADP-induced platelet aggregation, platelet-derive nitric oxide (PDNO) release, intraplatelet levels of GSH and GSSG, and intraplatelet nitrotyrosine production during platelet aggregation were measured. Fluvastatin and colestimide equally lowered total and low density lipoprotein cholesterol levels in hypercholesterolemia. Platelet aggregation was greater in hypercholesterolemia than in normocholesterolemia before treatment and was altered by fluvastatin. PDNO release, intraplatelet glutathione level, and GSH/GSSG ratio were lower in hypercholesterolemia than in normocholesterolemia before treatment and were increased by fluvastatin. Intraplatelet nitrotyrosine formation was greater in hypercholesterolemia than in normocholesterolemia, and decreased by fluvastatin. Colestimide did not have such effects. In vitro application of fluvastatin dose-dependently inhibited platelet aggregation. Furthermore, in vitro application of fluvastatin dose-dependently inhibited platelet nitrotyrosine expressions and the inhibitory effects by fluvastatin were reversed by preincubation with geranylgeranylpyrophosphate. Conclusions-Fluvastatin altered platelet aggregability in hypercholesterolemic patients in a cholesterol-lowering independent manner, which was partly mediated by the improvement of intraplatelet redox imbalance. (Arterioscler

Atorvastatin Inhibits gp91 phox Circulating Levels in Patients With Hypercholesterolemia

“…4 Reduction of several markers of oxidative stress including isoprostanes, , and nitrotyrosine have been observed after statin treatment but the underlying mechanism is still unclear. [5][6][7][8][9] In a pilot study performed in patients with chronic granulomatous disease (X-CGD), a very rare life-threatening disease secondary to hereditary deficiency of gp91 phox (the catalytic subunit of phagocyte NADPH oxidase), we found a significant reduction of urinary isoprostanes. 10 Also, in children with hypercholesterolemia, we observed a significant correlation between platelet gp91 phox expression and urinary isoprostanes.…”

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

“…Statins can also decrease platelet activation by modulating the NO bioavailability in platelets (Laufs et al, 2000;Haramaki et al, 2007;Lee et al, 2010) and rapidly reducing the CD36 and lectin-like ox-LDL receptor-1 (Mehta et al, 2001;Puccetti et al, 2005), specific receptors for ox-LDL that are considered potent platelets agonists. Furthermore, statins inhibit the platelet-induced tissue factor expression by monocytes and macrophages (Puccetti et al, 2000), counteracting the prothrombotic complications of atherosclerosis (Aikawa et al, 2001).…”

Spectrum of Pleiotropic Effects of Statins in Heart Failure

“…[40] In a human study, fluvastatin was shown to decrease platelet aggregation in a mechanism thought to be mediated by increased platelet derived nitric oxide release. [41] In a rat model of streptozotocin-induced diabetes, rosuvastatin has been shown to reduce fibrinogen binding to activated GPIIb/IIIa and P-selectin surface expression on platelets. [42] In a small clinical study, 17 patients received atorvastatin 10mg/day, whereas 18 patients received no statin therapy.…”